The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

Common viral respiratory infections such as COVID-19, respiratory syncytial virus (RSV) and influenza are linked to an ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

U.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The flu virus is lingering in Arizona and the season has been vicious. Pediatric flu deaths reached the highest level in ...

on Wednesday to recommend that high-risk patients ages 50 to 59 be vaccinated for respiratory syncytial virus (RSV), and also added a new option for meningococcal vaccination. "I don't think I can ...

Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting ...

2025 GSK applies to EU regulator for expanded use of RSV vaccine GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the ...